Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00761436 · ClinicalTrials.gov registry record · Phase 2
Pilot Study of Safety and Efficacy of Spheramine
A Phase 2 study, sponsored by Bayer.
- Terminated
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT00761436 is a Phase 2 study that was terminated before completion, run by Bayer. The registered enrollment target is 6 participants.
The verdict
NCT00761436, a Phase 2 study, was terminated before completion, sponsored by Bayer.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
Tolerability and Efficacy of Spheramine will be evaluated after operative implantation (Stereotactic Intrastriatal Implantation) in patients with advanced Parkinson's Disease
Interventions
- BIOLOGICAL Spheramine (BAY86-5280)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2000-02-29 |
| Est. Completion | 2012-05-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00761436
The ClinicalTrials.gov registry entry for NCT00761436 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Spheramine (BAY86-5280) is the first listed.
NCT00761436 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00761436 about?
NCT00761436 is a clinical study titled "Pilot Study of Safety and Efficacy of Spheramine". Tolerability and Efficacy of Spheramine will be evaluated after operative implantation (Stereotactic Intrastriatal Implantation) in patients with advanced Parkinson's Disease
What is the current status of trial NCT00761436?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2000-02-29. Estimated completion is 2012-05-14.
What interventions are being tested in trial NCT00761436?
The interventions under investigation include: Spheramine (BAY86-5280) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00761436?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.